-
Hengrui Medicine's application for the listing of CDK 4/6 inhibitors has been accepted and R&D investment nearly 2...
Time of Update: 2021-05-10
On April 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Hengrui Medicine's Class 1 new drug CDK 4/6 inhibitor SHR6390 tablets had submitted a new drug marketing application and was accepted.
-
Microchip's partner submits Chidamide's listing application in Japan and is accepted
Time of Update: 2021-05-10
application (NDA) and was accepted. This is after the submission of a listing application for the first indication of Chidamide in Japan on September 30, 2020, another submission of a listing application for the second
-
Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.
Time of Update: 2021-05-10
On April 20, Microchip released an announcement that the Phase 2 trial of chidamide combined with envolimab in the treatment of non-small cell lung cancer (NSCLC) patients who have been treated with PD-1 inhibitors has been received from China.
-
CStone's Pratinib thyroid cancer indication was accepted and included in priority review
Time of Update: 2021-05-10
/>
>®
Thyroid cancer is the most common endocrine malignant tumor, and its incidence has increased significantly in recent years. According to the data released
-
Roche Trastuzumab Injection's marketing application was accepted by CDE
Time of Update: 2021-05-09
On April 21, Roche's application for the marketing of trastuzumab injection (subcutaneous injection) was accepted by CDE, which means that this subcutaneous preparation will soon be available
-
Hua Medicine's first innovative diabetes drug Dozaglietin NDA was accepted by NMPA!
Time of Update: 2021-05-09
that during the treatment period, dozaglietin can take effect quickly, continuously and effectively reduce glycated hemoglobin, and significantly reduce the blood glucose level two hours after a meal. It has good safety and tolerability
-
inhibitor Pugeta® (Platinib Capsules) has been accepted by the National Medical Products
Time of Update: 2021-05-08
due to new information, future events or other reasons after the date of making such statements, or to reflect the occurrence of unexpected events. Please read the full text and understand that our actual future results
-
Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.S.
Time of Update: 2021-05-02
) is a recombinant humanized PD-L1 single domain antibody Fc fusion protein injection that can be injected subcutaneously. It has submitted a new drug application in China and has been included in the priority review. The indication
-
The clinical trial application of BPI-16350 drug combination treatment of breast cancer by Betta Pharmaceuticals has been accepted
Time of Update: 2021-05-02
The company declared that BPI-16350 capsules combined with fulvestrant or aromatase inhibitors can treat breast cancer The application for clinical trials of drugs has been accepted by the State Food and Drug Administration.
-
Epoxy resin: the end of the third quarter shocks, the profits of the manufacturers are acceptable
Time of Update: 2021-05-01
Continued to weaken, manufacturers actively offered to make profit under the pressure of shipments, and the market spot price entered a rapid downward channel.
-
[News] Graphene modified heavy-duty anti-corrosion coating passed acceptance
Time of Update: 2021-05-01
According to reports, under the promotion of the national project, the team of Academician Xue Qunji and Researcher Wang Liping of the Ningbo Institute of Materials of the Chinese Academy of Sciences successfully developed graphene modified heavy-duty anti-corrosion coatings.
-
Precautions and daily maintenance of wood paint construction acceptance
Time of Update: 2021-04-29
, and the texture is natural, usually the wood lacquer is transparent. At the time of acceptance, pay attention to whether the lines on the surface of the wood are clear, whether the brown eyes are scratched, and whether there is any
-
Dongyangguang: Application for drug registration of insulin aspart injection has been accepted
Time of Update: 2021-04-28
(hereinafter referred to as "Dongyang Pharmaceutical") insulin aspart injection had received the "Notice of Acceptance" issued by the State Food and Drug Administration.
-
Ganli Pharmaceutical's GZR18 clinical application was accepted by NMPA
Time of Update: 2021-04-27
For obesity and overweight indications, currently, no GLP-1 receptor agonist drug that is injected once a week has been approved for obesity and overweight treatment globally.
-
Huahai Pharmaceutical Sitagliptin Phosphate Tablets Received Acceptance from CDE
Time of Update: 2021-04-27
0 Chinese Drug Evaluation DatabaseAt present, the only companies approved for sitagliptin phosphate tablets in the domestic market are Merck and Dongyang Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group.
-
FDA accepts AbbVie Atogepant new drug application for preventing migraine in adults
Time of Update: 2021-04-24
CompileriverOn March 30, AbbVie announced that the FDA has accepted Atogepant's New Drug Application (NDA), a research oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the prevention of meeting the criteria for paroxysmal migraine Of adult migraines.
-
Daily Review of BPA: Mindset is acceptable
Time of Update: 2021-04-24
in mid-May; Zhongxin Chemical’s early factory quotation 16,900 yuan/ton, an increase of 900 yuan/ton from before the closure. The 25,000-ton/year bisphenol A plant is operating smoothly and may be shut down in early May for maintenance.
-
Langlai Technology's IRAK4 inhibitor MY004 clinical trial application was accepted by NMPA
Time of Update: 2021-04-24
The purpose of the clinical study of MY004 application acceptance is to explore the safety, tolerability and pharmacokinetic properties of the drug in healthy subjects.
-
Seven domestic new crown vaccines are being accepted by WHO's emergency use list. Experts call
Time of Update: 2021-04-24
and huge challenge is presented, which is prominently manifested as "how to be excellent" and "how to be strong. ">So, how should the Chinese vaccine industry accelerate the process of internationalization
-
Xianju Pharmaceutical Receives Acceptance Notice for Consistency Evaluation of Dexamethasone Sodium Phosphate Injection
Time of Update: 2021-04-24
On April 6, Xianju Pharmaceutical issued an announcement stating that it had recently received a notice of acceptance of the consistency evaluation of dexamethasone sodium phosphate injection issued by the State Food and Drug Administration.
